Premium
Perspectives for new treatments at Alcon ‐ part 1
Author(s) -
RICH C
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.2724.x
Subject(s) - medicine , presentation (obstetrics) , glaucoma , cataract surgery , optometry , ophthalmology , surgery
This presentation will give the audience an overview of how we identify a wide variety of potential products to develop and how we condense this list down to the final candidates that will establish our pipeline strategy for each year. This process is conducted across the 3 main franchises of Alcon: Pharmaceuticals, Surgical and Vision Care. This presentation will review products in development in the areas of Glaucoma, Anterior Segment and the Ocular Surface. In the area of Glaucoma we currently have several products that will be reviewed. This includes potential new chemical entities with novel mechanisms of action and combination products that have the IOP lowering power greater than a beta‐blocker without the risk of a beta‐blocker. In the area of anterior segment we have several exciting programs in development to meet the unmet medical need around cataract surgery healing and post‐operative infection. In the area of the ocular surface we have several projects in development for improved treatment in allergy (both nasal and ocular) and dry eye. In addition, as an extension of this area, we have projects for the treatment of acute otitis externa and antibacterial use during the peri‐operative placement of tympanostomy tubes.